“Thrombi with the Janssen vaccine appear to be extremely rare”: Representatives of the Centers for Disease Control and Prevention of the United States (CDC) and the United States Food and Drug Administration (FDA) have held a press conference to discuss the suspension of vaccination with Janssen’s preparation against the Covid-19 coronavirus to be related to thrombi. In this sense, although they are going to carry out a more exhaustive review, they have assured that these adverse effects are “extremely rare”.
They have advised that people who have received the vaccine and develop symptoms of headache severe, abdominal pain, leg pain or shortness of breath within three weeks should go to the hospital. However, they have indicated that the risk of dangerous blood clots is “very low” for people who received the vaccine more than a month ago.
The CDC and FDA are reviewing data from six reported cases of a “rare and serious” type of blood clot in individuals after receiving the vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of platelets in the blood (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48., and symptoms appeared 6 to 13 days after vaccination.
See This: www.peryourhealth.com payment
Experts have explained that the treatment of this specific type of blood clot is different from the treatment that is normally given. Heparin is generally used to treat blood clots, but: “In this setting, giving heparin can be dangerous,” they say.
For its part, the European Medicines Agency (EMA) stressed this Tuesday that it is “investigating” the cases of thrombotic events detected in the United States after the Covid vaccination with Janssen’s drug. In addition, he assured that “it is currently unclear if there is a causal association.”
As indicated last Friday, the EMA Pharmacovigilance Committee (PRAC) was studying the six cases that had occurred in the United States after receiving the Janssen Covid vaccine.
This Tuesday, after knowing the decision of the FDA and the European Union, a spokeswoman for the agency has affirmed in statements to the Efe agency that “a review of a safety signal” is being carried out, and that the result of this will lead them to decide “if a regulatory action may be necessary.” Look into peryourhealth for getting more health updates.